Phase not reported / not applicableCompletedOBSERVATIONAL
A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
ClinicalTrials.gov · NCT04295005 · Registry updated: 2024-08-30
- Condition / research focus
- Diabetes Mellitus, Type 2
- Sponsor
- Boehringer Ingelheim
- Countries with listed sites
- Germany
- Registry dates and results
- Start: 2020-11-16. Completion: 2021-09-30 (may be estimated). Results are posted in this registry.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Empagliflozin (drug)
- DPP-4i (drug)
- GLP-1-RA (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Boehringer Ingelheim
Ingelheim, Germany
Site recruitment: Not reported